Drug intelligence / Profile preview

lorlatinib + temozolomide

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Lorlatinib + temozolomide is an investigational combination therapy consisting of lorlatinib, a third-generation ALK tyrosine kinase inhibitor, and temozolomide, an alkylating agent. This combination is being studied primarily for patients with ALK-positive cancers who have experienced central nervous system (CNS) progression while on ALK inhibitor therapy. The rationale for this combination is based on temozolomide's CNS penetration capabilities and mechanism of action, which may complement lorlatinib's activity against ALK-positive tumors to provide improved control of CNS disease.

Targets

ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)DNA

Beyond the preview

Go deeper on lorlatinib + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lorlatinib + temozolomide.

Explore the full profile